Anthrax Treatment Market Size Projected to Reach $721.81 million by 2034 | 5.5%

According to Straits Research, the global anthrax treatment market size was valued at $391.57 million in 2025 and is projected to grow from $421.48 million in 2026 to $759.54 million by 2034 at a CAGR of 7.64% during the forecast period 2026-2034.

Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis. Treatment primarily depends on the form of anthrax—cutaneous (skin), inhalation, gastrointestinal, or injection. Antibiotics such as ciprofloxacin, doxycycline, and penicillin are the first-line treatments and are most effective when administered early. Moreover, inhalation anthrax, the most severe form, often requires a combination of intravenous antibiotics and antitoxins to counteract the bacterial toxins. Supportive care, including ventilators, fluid therapy, and medications to stabilize blood pressure, may be necessary for severe cases.

Market Dynamics

Rising incidents of zoonotic diseases drive the global market

The growing incidence of zoonotic diseases, including anthrax, is a major factor driving the global market. Expanding agricultural activities, climate change, and increased human-livestock interactions have heightened the risk of disease transmission. Outbreaks in cattle, sheep, and other livestock continue to pose serious public health risks, fueling the demand for effective vaccines, diagnostics, and treatment solutions.

• For example, in November 2023, Zambia experienced a severe anthrax outbreak, resulting in over 200 suspected human cases and the deaths of hundreds of livestock. This crisis prompted health authorities to implement emergency vaccination campaigns to contain the spread. The escalating threat of zoonotic diseases is prompting greater investments in disease surveillance and livestock immunization programs, significantly contributing to market expansion.

Increased focus on biodefense creates tremendous opportunities

Governments worldwide are strengthening biodefense measures to counter bioterrorism threats, creating substantial growth opportunities. With Bacillus anthracis classified as a high-priority biothreat agent, there has been a significant rise in investments for research, vaccine stockpiling, and rapid response strategies. Concerns over potential outbreaks and bioterrorism have driven increased funding and government contracts for pharmaceutical companies developing anthrax vaccines, diagnostics, and therapeutics.

• For instance, in January 2024, the U.S. Department of Defense awarded Emergent BioSolutions a $235.8 million contract to supply BioThrax, an anthrax vaccine, for military personnel as a pre-exposure prophylaxis. This initiative is part of a broader national defense strategy to safeguard the armed forces against biological threats.

Regional Analysis

North America dominates the global anthrax treatment market, driven by strong biodefense initiatives, advanced healthcare infrastructure, and substantial R&D investments. The U.S. government prioritizes anthrax preparedness through extensive stockpiling of vaccines and antibiotics to counter potential bioterrorism threats. Agencies such as the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense (DoD) actively fund research and procurement programs to enhance national biosecurity. The region's well-equipped hospitals, research institutions, and specialized diagnostic centers enable rapid detection and treatment of anthrax cases.

Key Highlights

• According to Straits Research, the global anthrax treatment market size was valued at $391.57 million in 2025 and is projected to grow from $421.48 million in 2026 to $759.54 million by 2034 at a CAGR of 7.64% during the forecast period 2026-2034.
• Based on disease type, the global market is segmented into cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax, and injection anthrax. The inhalation anthrax segment is the largest revenue contributor to the market.
• Based on treatment type, the global anthrax treatment market is segmented into antibiotics, immunoglobulins, and others. The antibiotics segment is the largest revenue contributor to the market.
• Based on the route of administration, the global market is segmented into parenteral and oral. The parenteral segment is the largest revenue contributor to the market.
• Based on end-users, the global anthrax treatment market is segmented into hospitals, clinics, and others. The hospital segment is the largest revenue contributor.
• North America is the highest shareholder in the global market.

Market Segments

1. By Disease Type
   1. Cutaneous Anthrax
   2. Inhalation Anthrax
   3. Gastrointestinal Anthrax
   4. Injection Anthrax
2. By Treatment Type
   1. Antibiotics
   2. Immunoglobulins
   3. Others
3. By Route of Administration
   1. Parenteral
   2. Oral
4. By End-User
   1. Hospitals
   2. Clinics
   3. Others
5. By Regions
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Central & South America
   5. The Middle East and Africa